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Hyperthermia induced HIF-1a expression of
lung cancer through AKT and ERK signaling
pathways
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Abstract
Background: Hyperthermia is a promising treatment for human lung cancer, but recurrence of the primary lesion is
common, as the residual tumor becomes adapted to heat treatment and growth is induced by hypoxia-triggered
HIF-1a expression. Here, we explored the effects of hyperthermia on HIF-1a expression, proliferation, and lung
cancer angiogenesis.
Methods: Human NSCLC NCI-H1650 and SCLC NCI-H446 cell lines were used to examine cell viability, apoptosis,
and HIF-1a expression level under a gradient of thermal conditions (37, 42 and 47 °C for 40 min). The 47 °C
heat-adapted NCI-H1650 and NCI-H446 sublines (also called NCI-H1650-b and NCI-H446-b cells) had enhanced
viability and HIF-1a expression levels compared to the parental and 42 °C heat-adapted cells and were thus
used for subsequent research. Concentration gradients of wortmannin and PD98095 were used to inhibit AKT
and ERK expression, respectively in the NSCLC NCI-H1650-b and SCLC NCI-H446-b cell lines, and cell growth
curves were drawn. Western blots were used to detect the expression of HIF-1a, extracellular signal-regulated
kinase (ERK), protein kinase B (AKT), phospho-ERK, and phospho-AKT. We established a subcutaneous transplantation
tumor model with wortmannin and PD98095 intervention. Immunohistochemistry was used to detect the expression
of HIF-1a and the vascular specific marker CD34, and tumor growth curves were drawn.
Results: Following hyperthermia treatment, HIF-1a expression in 47 °C heat-adapted NSCLC and SCLC cell lines was
regulated by the AKT pathway. However, HIF-1a expression was also regulated by the ERK pathway in NSCLCs, while
SCLCs did not exhibit changes in ERK. These biological behaviors are governed by signaling pathway protein
phosphorylation. Furthermore, inhibiting the AKT pathway can suppress the proliferation and angiogenesis
potential of both 47 °C heat-adapted NSCLCs and SCLCs, but inhibiting the ERK pathway only affects SCLCs.
Conclusion: Our study suggests that following hyperthermia, the proliferation and angiogenesis potential of
residual NSCLCs and SCLCs is induced by HIF-1a. However, HIF-1a expression in NSCLCs is regulated by both
the AKT and ERK signaling pathway, but HIF-1a expression in SCLCs is regulated only by the AKT signaling
pathway. This study sheds light on the molecular regulatory mechanisms of lung cancer recurrence following
hyperthermia treatment.
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Background
In recent years, hyperthermia has been recognized as a
clinical treatment for certain cancers (e.g. lung cancer),
which can be induced by therapeutic techniques, such as
radiofrequency ablation (RFA). However, one of the
major problems with hyperthermia is that it is difficult
to achieve complete tumor destruction using this tech-
nique, and recurrence is common, because the residual
tumor is now adapted to heat treatment and growth is
induced [1]. Accumulating evidence indicates that both
hypoxia and hypoxia-driven angiogenesis are the conse-
quence of hyperthermia, and both of these factors play
important roles in tumor growth [2]. Under conditions
of hypoxia, a signaling pathway involving a crucial oxy-
gen response regulator, defined hypoxia-inducible factor
(HIF), is turned on. HIF protein, especially HIF-1α and
HIF-2α, are correlation with tumor development, metas-
tasis and promote epithelial-mesenchymal transition [3].
In contrast with HIF-2α, which is expressed in certain
cell types of vertebrate species, the expression of HIF-1α
is observed in most metazoan species and involved in
the regulation of epithelial-mesenchymal transition of
tumor [4]. As a key transcriptional regulator, HIF-1α
plays a central role in the adaptation of tumor cells to
hypoxia and helps to regulate the expression of muitiple
cytokines, such as vascular endothelial growth factor-A
(VEGF-A), and promotes the proliferation [5] and angio-
genesis potential [6] of small cell lung cancers (SCLCs).
Earlier research also showed that HIF-1a is involved in
apoptosis and the proliferation of non-small cell lung
cancers (NSCLCs) [7, 8]. In our previous study, we
found that local recurrences of SCLC following RFA
treatment were driven by HIF-1a, while the thermal ef-
fects of RFA can promote the growth of residual
NSCLCs by up-regulating HIF-1a expression [9].
The expression and activity of HIF-1a is not only in-
duced in response to limited oxygen availability, but it
is also modulated through related signaling pathways
[10]. Some studies have demonstrated that the expres-
sion of HIF-1a is regulated by major signaling path-
ways, including the extracellular signal-regulated
kinase (ERK) pathway [11] and the protein kinase B
(AKT) pathway [12]. Intensive studies of the ERK and
AKT pathways have revealed these signaling pathways
play their most important roles in the molecular sig-
naling network that governs growth, proliferation, dif-
ferentiation and survival in many, if not all, cell types
[13, 14]. Therefore, to uncover the molecular mecha-
nisms of lung cancer recurrence following hyperther-
mia treatment, the present study explores the effects
of hyperthermia on HIF-1a expression and cell prolif-
eration and angiogenesis. We then went on to investi-




Specific inhibitor wortmannin, PD98059, and Recombinant
Human Heregulin were purchased from Sigma, St. Louis,
MO, USA. TRIzol reagent was purchased from Invitrogen,
Carlsbad, CA. RIPA lysis buffer was purchased from the
Beyotime Institute of Biotechnology, China. The following
primary antibodies: anti-CD34 (1:40 dilution), anti-HIF-1a
(1:500 dilution), anti-ERK1/2 (1:1000 dilution), and anti-
AKT (1:1000 dilution) were purchased from Wuhan Boster
Biological Engineering Technology Limited Company.
Anti-phospho-AKT (1:1000 dilution) was purchased from
Cell Signaling Technology, Beverly, MA, USA. and anti-
phospho-ERK1/2 (1:800 dilution) was purchased from
Santa Cruz, CA, USA.
Cell culture, heat treatment of cells, and establishment of
sublines
Human NSCLC NCI-H1650 cells and SCLC NCI-
H446 cells were maintained in RPMI-1640 medium
(Sigma-Aldrich Co., St. Louis, MO, USA) supplemented
with 10 % fetal bovine serum (FBS), 100 units/mL penicil-
lin, and 100 μg/ml kanamycin at 37 °C in a humidified at-
mosphere containing 5 % CO2 and 20 % O2. The medium
was routinely changed 2-3 days after seeding. Cells were
detached with trypsin/EDTA (GibcoBRL, Paisley, UK) and
were resuspended in a 1:1 solution of serum-free RPMI-
1640 medium to a final concentration of approximately
5× 105 cells/10 μl.
During the exponential phase, cells were exposed to
hyperthermic stress in cell culture plates for 24, 48, or
72 h. The plates were sealed with parafilm and sub-
merged in a water bath at the desired temperature for
10 min. The three desired temperatures were 37, 42, and
47 °C. The cells cultured at 42 and 47 °C generated 2 cell
sublines each, named NCI-H1650-a and NCI-H1650-b;
NCI-H446-a and NCI-H446-b respectively. After the
hyperthermic treatment, fresh culture medium was
added to each well, and the surviving cells were main-
tained at 37 °C with an atmosphere containing 5 % CO2
and 1 % O2 for 4 h. After determining cell viability and
HIF-1a expression levels, we chose one subline for the
following experiment.
TUNEL staining for apoptosis assay
Cells were grown on coverslips, treated with 5 μM BIX
for 48 h and stained with Click-iT plus TUNEL assay kit
(Invitrogen) according to previous study [15]. Then, cells
were washed with PBS, fixed in 4 % paraformaldehyde
(PFA) for 20 min, and permeabilized with 0.25 % Triton
X-100 for 15 min. The cells were incubated with TdT re-
action buffer for 10 min, then TdT reaction mixture for
1 h, and then incubated with TUNEL reaction cocktail
for 30 min. Incubation with 0.05 % Diaminobenzidine
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Fig. 1 The viability of NCI-H1650 cells and NCI-H446 cells and their sublines adapted to hyperthermia treatment. a NCI-H1650 and NCI-H446 cells
are cultured under 37, 42, and 47 °C. Apoptosis rate is measured using a Tunnel staining assay. The brown stained cells are apoptocic cells, and
semi-quantitative analysis of apoptosis rates are measured. (*p < 0.05 37 °C vs 42 °C heat treatment group, **p < 0.05 47 °C vs 42 °C heat treatment
group) (b) 2 sublines were established following incubation at 42 and 47 °C. The 24, 48, and 72 h viability was evaluated by MTT assay. Parental
cells: cells cultured under 37 °C; NCI-H1650-a and NCI-H446-a subline: cells adapted to 42 °C heat treatment; NCI-H1650-b and NCI-H446-b subline:
cells adapted to 47 °C heat treatment (*p < 0.05 NCI-H1650-a or NCI-H446-a subline vs parental cells, **p < 0.05 NCI-H1650-a subline vs NCI-H1650-b
subline, NCI-H446-a subline vs NCI-H446-b subline) (c) Growth curve of parental cells and the cells subline a and b are drawn. Data are the representative
results of three independent experiments (*p< 0.05 from day 2-7 parental cells vs cells subline-a, **p< 0.05 from day 2-7 cells subline-a vs cells subline-b).
d HIF-1a expression of parental cells, the cell subline a and b are detected by Western-blot and semi-quantitative analysis. (*p< 0.05 parental cells vs cells
subline-a, **p< 0.05 cells subline-a vs cells subline- b)
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tetrahydrochloride (DAB) solution for 8 min was used
for counterstaining. Cells were examined using a Nikon
microscope with Image-Pro Plus 6.x software (Diagnostic
Instruments, USA) for image analysis.
MTT assay for lung cancer cells viability
Cells were cultured at a concentration of 1 × 104 cells/
well in 48-well plates. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) solution was
added to each well at a final concentration of 0.5 mg/ml
and incubated for 4 h. At the end of the incubation, for-
mazan crystals, resulting from MTT reduction, were dis-
solved by addition of 150 ml DMSO per well. The
optical density was read at 570 nm, and the average
values were determined from replicate wells.
Growth of xenografts in nude mice
Male congenital athymic BALB/c nude mice were ob-
tained from the Experimental Animal Center of the
Shang Hai Jiao Tong University School of Medicine.
They were maintained under pathogen-free conditions
in accordance with established institutional guidance
and approved protocols. All experiments were carried
out using 6-8-week-old mice weighting 16-22 g. Sublines
of NCI-H1650 and NCI-H446 cells were cultured in
vitro (1 × 107), and a final concentration of approxi-
mately 5 × 105 cells/10 μl were suspended in PBS and
subcutaneously injected into the flank area of mice.
After tumors reached 3-5 mm in diameter, mice were
injected with either vehicle (10 % DMSO/PBS), 4 mg/kg,
or 5 mg/kg twice weekly. The tumor size was measured
with calipers every 3 days, and tumor volume was calcu-
lated according to the formula: volume = width2 ×
length × 0.5. Tumors were removed and weighed 30 days
after inoculation. All surgical procedures were per-
formed under isoflurane inhalation anesthesia. Bupre-
norfine was injected intramuscularly prior to surgery for
perioperative analgesia.
Immunohistochemistry detection for HIF-1a and vascular
specific markers
All tumor tissue sections were cut into 4 μM sections,
deparaffinized, and endogenous peroxidases were inhib-
ited with 0.3 % hydrogen peroxide in methanol for
30 min. Antigen retrieval was achieved using 0.05 % pro-
tease XIV at 37 °C for 5 min. Sections were then incu-
bated with a mouse anti-human HIF-1a or CD34
primary antibody overnight at 4oC. Next, the slides were
incubated with biotin-conjugated rabbit anti-mouse
secondary antibody at room temperature for 45 min.
The sections were subsequently incubated with a
streptavidin-biotin-peroxidase complex (Vectastain ABC
kit, Vector Laboratories, Burlingame, CA, USA) at room
temperature for 45 min. The reaction was visualized
using chromogen diaminobenzidine (DAB) for 10 s. Fi-
nally, the slides were counterstained with hematoxylin
and mounted. The slides were examined with a Nikon
Eclipse Ti microscope under a 40X objective.
Western-blot analysis of HIF-1a and signaling protein
Cells and tissues were harvested and analyzed for the ex-
pression of HIF-1a, ERK, p-ERK, AKT, and p-AKT.
Briefly, total protein was extracted by disrupting cells in
RIPA lysis buffer and separating on a polyacrylamide gel
and transferring to PVDF membrane. The membranes
were then blocked at room temperature for 1 h with 5 %
non-fat milk in Tris buffered saline containing Tween 20
(TBST). The membrane was incubated with anti-HIF-1a,
anti-ERK1/2, anti-AKT, anti-phospho-AKT, and anti-
phospho-ERK1/2 primary antibodies at 37oC for 2 h,
and then with peroxidase-conjugated IgG at room
temperature for 1 h. The membranes were subsequently
incubated with goat anti-rabbit peroxidase-conjugated
secondary antibodies, and immunoreactivity was de-
tected by using an enhanced chemiluminescence kit, and
captured on X-ray film. β-actin was used as an internal
control.
Fig. 2 Wortmannin inhibits HIF-1a expression in NSCLC and SCLC
cells following 47 °C heat treatment. NCI-H1650-b and NCI-H446-b
sublines are cultured to 80-90 % confluence and exposed to hypoxia.
a NCI-H1650-b and NCI-H446-b sublines are pretreated with different
concentrations of wortmannin exposed to 1 % oxygen. HIF-1a
protein expression level is measured by Western blot. b The result of
semi-quantitative analysis show that with increasing concentrations of
wortmannin, HIF-1a expression in the NCI-H1650-b and NCI-H446-b cell
sublines decreased gradually (*p < 0.05 between different groups)
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Statistical analysis
The SPSS 13.0 software (SPSS, USA) was applied to
complete data processing. An independent-samples t-test
was used to evaluate the differences in optical density (OD)
values or tumor cell numbers between groups with various
treatments. All data are represented as the mean ± SD for
three independent experiments. Results were considered
statistically significant when the p-value was less than 0.05.
Results
In vitro heat treatment can generate NCI-H1650 cell
sublines with increased viability
To detect the potential effect of hyperthermia on the pro-
liferative activity of lung cancer cells, first we monitored
cell viability at 24, 48, and 72 h after incubation at 37, 42,
or 47 °C for 10 min. We found that the apoptosis rate of
NCI-H1650 and NCI-H446 cells after incubation at 47 °C
was significantly higher compared to cells incubated at
37 °C or 42 °C (Fig. 1a). In addition, the apoptosis rate of
cells incubated at 42 °C was higher than at 37 °C. The cells
cultured at conventional culture temperature (37 °C) are
called parental cells, and the cells cultured and adapted to
42 and 47 °C were named the NCI-H1650-a and NCI-
H446-a and NCI-H1650-b and NCI-H446-b sublines
respectively. The cellular viability of parental cells and
sublines all reach their highest viability at 72 h. However,
the cell viability of sublines adapted to 47 °C are higher
than the sublines adapted to 42 °C or the parental cells.
The viability of sublines adapted to 42 °C are higher than
parental cells (Fig. 1b). From the growth curve, we can see
that the proliferation activity of sublines adapted to 47 °C
are higher than the sublines adapted to 42 °C or the
parental cells (Fig. 1c). Furthermore, the HIF-1a expres-
sion level of sublines adapted to 47 °C is also higher than
the subline adapted to 42 °C or the parental cells (Fig. 1d).
Therefore, we conclude that thermal treatment can
partially kill lung cells, while generating sublines with
increased viability with higher HIF-1a expression levels.
Therefore, we used the NCI-H1650 subline adapted to
47 °C for our subsequent experiments.
Specific inhibitor wortmannin inhibited HIF-1a expression,
and the proliferation, and angiogenesis potential of
NSCLCs and SCLCs following 47 °C heat treatment
We investigated the effect of Akt signaling on HIF-1a
expression in both NSCLC NCI-H1650 cells and SCLC
Fig. 3 Effect of Wortmannin or PD98095 on the proliferation of NSCLC and SCLC following heat treatment. In vitro, the NCI-H1650-b and NCI-
H446-b sublines (in logarithmic phase) are treated with wortmannin or PD98095 (40 μM). We compared the growth curve of the cells in control
group, wortmannin group, and PD98095 group. a When the NCI-H1650-b subline was treated with wortmannin or PD98095, the growth curve
shifted to the right and the growth rate was slowed (*p < 0.05 wortmannin group vs control group, **p < 0.05 PD98095 group vs control group).
b When the NCI-H446-b subline was treated with wortmannin, the growth curve shifted to right and the growth rate was significantly slowed
(*p < 0.05 wortmannin group vs control group), but after treatment with PD98095, the growth curve changed very little (**p > 0.05 PD98095 group
vs control group). c The growth curve of subcutaneous tumors formed by the NCI-H1650-b subline show that after treatment with wortmannin or
PD98095, the curve moved right (*p < 0.05 wortmannin group vs control group, **p < 0.05 PD98095 group vs control group). d The growth
curve of SCLC transplantation tumors shows that treatment with wortmannin but not PD98095 causes the rightward movement of growth curve
(*p < 0.05 wortmannin group vs control group, **p > 0.05 PD98095 group vs control group)
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NCI-H446 cells adapted to 47 °C. Because HIF-1a ex-
pression in the NCI-H1650-b and NCI-H446-b sublines
was elevated, we cultured the cells under hypoxic con-
ditions (1 % oxygen concentration). Wortmannin, a
specific inhibitor of the Akt signaling pathway, reduced
HIF-1a protein expression in a dose-dependent manner
in both the NCI-H1650-b and NCI-H446-b cell sub-
lines (Fig. 2a, b). From the cell growth curve, we found
that the proliferation of the NCI-H1650-b and NCI-
H446-b sublines was inhibited by wortmannin (Fig. 3a,
b). To further evaluate the effect of AKT signaling on
HIF-1a expression and angiogenesis potential, we next
examined the effects of wortmannin on NCI-H1650-b
and NCI-H446-b subline xenografts. NCI-H1650-b and
NCI-H446-b subline cells were injected into the flanks
of athymic BALB/c nude mice to facilitate development
of a xenograft. One week following injection of the
tumor cells, wortmannin mixed with 5 % sodium bicar-
bonate was intraperitoneally delivered daily for three
weeks. We found that the growth of the tumor xeno-
grafts was significantly inhibited by wortmannin
(Fig. 3c, d), while immunohistochemical staining
Fig. 4 The effect of wortmannin and PD98095 on HIF-1a expression and angiogenesis potential in NSCLC and SCLC subcutaneous tumors following
heat treatment. NCI-H1650-b and NCI-H446-b sublines are subcutaneously injected into nude mice to form transplantation tumors. a Analysis
of immunohistochemistry indicates HIF-1a expression in NSCLC and SCLC subcutaneous tumor before and after treatment with wortmannin
or PD98095. b According to the results of semi-quantitative analysis, HIF-1a expression in NSCLCs following heat treatment is inhibited after
treatment with wortmannin or PD98095. HIF-1a expression in SCLCs is inhibited by wortmannin but does not change significantly with
PD98095 treatment (HIF-1a in control group vs wortmannin group: NCI-H1650-b *p < 0.05, NCI-H446-b **p < 0.05, HIF-1a in control group vs
PD98095 group: NCI-H1650-b ※p < 0.05, NCI-H446-b ※※p > 0.05) (c) Analysis of immunohistochemistry indicates changes in CD34 expression
in NSCLC and SCLC subcutaneous tumors before and after treatment with wortmannin or PD98095. d The results of semi-quantitative analysis
show that CD34 expression in NSCLCs following heat treatment is inhibited after treatment with wortmannin or PD98095. CD34 expression
in SCLCs is inhibited by wortmannin, but changes little after treatment with PD98095 (CD34 in control group vs wortmannin group: NCI-H1650-b
*p < 0.05, NCI-H446-b **p < 0.05, CD34 in control group vs PD98095 group: NCI-H1650-b ※p < 0.05, NCI-H446-b ※※p > 0.05)
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showed HIF-1a and CD34 expression was significantly
decreased (Fig. 4a-d).
Specific inhibitor PD98095 inhibited HIF-1a expression,
proliferation, and angiogenesis potential in NSCLCs but
not SCLCs following 47 °C heat treatment
To determine if ERK signaling affected HIF-1a ex-
pression in NSCLC NCI-H1650 and SCLC NCI-H446
cells adapted to 47 °C, we used the ERK specific in-
hibitor, PD98095. PD98095 inhibited hypoxia-induced
HIF-1a protein expression in a dose-dependent man-
ner in NCI-H1650-b cells (Fig. 5a, b), while inhibiting
cell proliferation (Fig. 3a). On the contrary, HIF-1a
expression was not inhibited by PD98095 in NCI-
H1650-b cells (Fig. 5a, b); proliferation of these cells
was also unaffected (Fig. 3b). After the establishment
of NCI-H1650-b and NCI-H446-b subline xenografts,
we injected PD98095 mixed with 5 % sodium bicar-
bonate daily for three weeks. We found that the growth
of the NSCLC tumor xenografts was inhibited by
PD98095 (Fig. 3c), while immunohistochemical staining
showed that HIF-1a and CD34 expression was signifi-
cantly decreased (Fig. 4a-d). However, PD98095 had no
obvious effect on the growth of the SCLC tumor xeno-
grafts (Fig. 3d), and HIF-1a and CD34 expression in
this tumor tissue showed only marginal changes
(Fig. 4a-d).
HIF-1a expression in the NSCLC cell subline adapted to
47 °C was induced by both AKT and ERK signaling
We next studied the signaling pathways regulating the
proliferation and angiogenesis potential of NSCLC cells
adapted to 47 °C. Previous reports confirmed that AKT
and ERK signaling pathways are involved in regulating
the important biological characteristics of tumors de-
rived from multiple tissue sources. To characterize the
roles of AKT and ERK in regulating HIF-1a expression,
wortmannin and PD98059 were used again. NCI-H1650-
b cells were cultured under hypoxic conditions, follow-
ing treatment by heregulin, which induces HIF-1a ex-
pression [16]. We found that AKT and ERK total
expression levels did not change much with treatment,
but the abundance of their phosphorylated forms, p-
AKT and p-ERK, increased in a dose dependent manner
(Fig. 6a). These results indicate that the phosphorylated
forms of AKT and ERK play a major role in the regula-
tion of HIF-1a expression. To confirm this finding, we
pre-treated NCI-H1650-b cells with the heregulin and
then treated with wortmannin or PD98095 and incu-
bated under hypoxic conditions for 6 h. Our study
showed that wortmannin abolishes heregulin-induced
HIF-1a expression, and PD98059 also significantly atten-
uates HIF-1a expression (Fig. 6b). Taken together, these
results indicate that the inactivation of the AKT and
ERK signaling pathways is important for the inhibition
of HIF-1a expression in NSCLCs following hyperthermic
treatment.
HIF-1a expression of the SCLC cell subline adapted to
47 °C is induced by the AKT, but not the ERK signaling
pathway
Because we found that the AKT and ERK signaling path-
ways were both involved in regulating HIF-1a expression
in NSCLCs following hyperthermic treatment, we inves-
tigated the role of these pathways in HIF-1a regulation
in SCLCs. As with NSCLCs, heregulin upregulated p-
AKT expression in a dose-dependent manner, but had
little effect on p-ERK expression (Fig. 7a). We pre-
treated the NCI-H446-b cell subline with heregulin and
then followed with wortmannin or PD98095, incubating
under hypoxic conditions for 6 h. Our study showed that
wortmannin also abolished heregulin induction of HIF-
1a expression in the NCI-H446-b cell subline (Fig. 7b).
Fig. 5 PD98095 inhibits HIF-1a expression in NSCLC cells but not
SCLC cells following heat treatment. After cultured to 80-90 %
confluence, NCI-H1650-b and NCI-H446-b cell sublines are exposed
to hypoxia and harvested to determine HIF-1a expression levels.
a NCI-H1650-b and NCI-H446-b cell sublines are also treated by
different concentrations of PD98095 exposed to 1 % oxygen. HIF-1a
protein expression level is measured by Western blot. b The result
of semi-quantitative analysis shows that with increasing concentrations
of PD98095, HIF-1a expression in NCI-H1650-b sublines decreases
gradually (*p < 0.05 between different groups), and the greatest
degree of inhibition occurred at a concentration of 40 μM. However,
the HIF-1a expression level of the NCI-H446-b subline was not
affected by the concentration changes in PD98095 (※p > 0.05 between
different groups)
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Although PD98059 inhibits ERK, it had no significant ef-
fect on HIF-1a expression in SCLCs (Fig. 7b). These in-
dicate that: (1) AKT signaling pathways help to regulate
HIF-1a expression in both NSCLCs and SCLCs follow-
ing hyperthermic treatment, and (2) the change in p-
ERK expression has no significant relationship with
HIF-1a expression in SCLCs following hyperthermia.
Therefore, HIF-1a expression in SCLCs following
hyperthermia is not regulated through the ERK signal-
ing pathway.
Discussion
Lung cancer is a heterogeneous, complex, and challen-
ging disease to treat. Hyperthermia is an approach that
takes advantage of the biological effects of heat to target
tumors. Hyperthermia techniques have been the subject
of extensive research with the overall goal of medicine
development and equipment advancement [17]. Now,
hyperthermia is regarded as an effective treatment for
lung cancer, which may be as successful as surgery,
radiotherapy, and chemotherapy. At present, clinical
Fig. 6 HIF-1a expression in NSCLCs following heat treatment is regulated through both the AKT and ERK signaling pathways. NCI-H1650-b sublines
are seeded and pretreated with different concentrations of heregulin and then exposed to 1 % oxygen. Expression levels of AKT, ERK, phosphorylated
AKT, and phosphorylated ERK were determined by western blot analysis. a After treatment with heregulin, AKT and ERK total protein expression levels
showed no obvious change (*p > 0.05 between different groups), but p-AKT and p-ERK were significantly up-regulated (※p < 0.05 between different
groups). b NCI-H1650 –b cells are seeded and pretreated with wortmannin and PD98059, then treated with heregulin. Cells are harvested and protein
is detected by western blotting. When treated with heregulin, HIF-1a expression is significantly up-regulated (▲p < 0.05 heregulin group vs control
group), but is inhibited after co-treatment with wortmannin or PD98059 (*p < 0.05 heregulin group vs heregulin + wortmannin group or heregulin +
PD98059 group). Total AKT and ERK protein showed no significant changes, whether treated singly or co-treated with wortmannin or PD98059,
according to the analysis of optical density (※p > 0.05 heregulin group vs control group, heregulin + wortmannin group or heregulin + PD98059
group). However, p-AKT and p-ERK expression was up-regulated when cells were treated with heregulin, but was inhibited after co-treatement with
wortmannin or PD98059 (#p < 0.05 heregulin group vs control group, heregulin + wortmannin group or heregulin + PD98059 group)
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hyperthermia treatment methods for lung cancers in-
clude laser ablation, radiofrequency ablation, and mag-
netic hyperthermia [18]. Among these, radiofrequency
ablation is becoming an increasingly accepted treatment
for primary lung cancers in patients who are not candi-
dates for subsegmental resection or lobectomy [19]. The
prognosis for tumor patients has been closely correlated
with activation and expression level of HIF-1a which are
regulated by many factors such as DEC2 (differentiated
embryonic chondrocyte gene 2) [20]. Besides this, heat
treatment can cause hypoxia in the local tissue and
increase HIF-1a expression levels, which can induce the
over-proliferation of any residual tumors, leading to the
recurrence of lung cancer [21]. Additionally, the angio-
genesis potential increased by heat-induced hypoxia can
also play a role in the rapid growth of residual tumor
cells that have escaped heat ablation. This phenomenon
is often referred to as a “malignant transformation” [22].
Hypoxia conditions present with, or induced by, heat
treatment can be replicated in in vitro cell culture. The
cell lines we used were already established and used in
previous studies, so that further spontaneous
Fig. 7 HIF-1a expression in SCLCs following heat treatment was regulated through the AKT but not the ERK signaling pathway. The method used
was described in Fig. 6; NCI-H446-b subline cells are harvested and western blot analysis for protein expression is applied. a There were no
obvious changes in AKT and ERK total protein expression levels (※p > 0.05 between different groups). p-AKT was gradually induced with increasing
heregulin concentrations (*p < 0.05 between different groups), but p-ERK expression showed no significant change (#p > 0.05 between different
groups). b HIF-1a expression was upregulated after treated by heregulin (▲p < 0.05 heregulin group vs control group), but was inhibited
after co-treatment with wortmannin, but not PD98059 (*p < 0.05 heregulin group vs heregulin + wortmannin group, #p > 0.05 heregulin
group vs heregulin + PD98059 group). Total AKT and ERK protein levels also showed no significant changes between all treatment groups
(※p > 0.05 heregulin group vs heregulin + wortmannin group or heregulin + PD98059 group). p-AKT expression was upregulated when
treated by heregulin (★p < 0.05 heregulin group vs control group) and inhibited after co-treatment with wortmannin (◆p < 0.05 heregulin
group vs heregulin + wortmannin group). However, p-ERK expression in SCLCs was unaffected, regardless of heregulin or PD98059 treatment
(■p > 0.05 heregulin group vs control group, ●p > 0.05 heregulin group vs heregulin + PD98059 group)
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transformation under normal culture conditions would
be unlikely. Therefore, we concluded that the biological
microenvironment associated with tumor growth chan-
ged due to the exposure to heat stress. Heat-adapted
sublines became more proliferative, which became the
focus of our subsequent work to identify the molecular/
biological mechanisms involved in tumor recurrence.
In our previous study, HIF-1a was found overex-
pressed in many human cancers and various cell types,
and the levels of HIF-1a activity were correlated with
tumorigenicity, angiogenesis, and metastasis [23]. Its tar-
get gene, VEGF-A, is mainly regulated by HIF-1a at the
transcriptional level, and VEGF-A also plays a critical
role in tumor angiogenesis, growth, and metastasis.
Targeting the HIF-1a/VEGF-A axis may be a promising
strategy for combating tumor recurrences following
hyperthermia treatment [24]. There has been a signifi-
cant increase in the understanding of the importance of
the signaling pathways that regulate the biological be-
havior of both NSCLCs and SCLCs (e.g. proliferation
and angiogenesis) in recent years [25, 26]. Inhibitors of
HIF-1a represent a new tool for improved cancer therap-
ies [27]. A number of chemical, protein, and nucleic acid
inhibitors are included and classified based on their
mechanisms of inhibitory action. Among these, inhibit-
ing upsteam signaling to block HIF-1a expression has
proven effective [28]. HIF-1α is situated at the conver-
gence of multiple oncogenic and tumor suppressor path-
ways, including the PI3K/AKT and MAPK/ERK
pathways [29]. These signaling pathways are at the heart
of a molecular signaling network that governs growth,
proliferation, differentiation, and survival in many cell
types [30]. They are dysregulated in various diseases,
ranging from cancer to immunological, inflammatory,
and degenerative syndromes, and thus represent an im-
portant drug target [31, 32]. A previous study found that
activating the AKT and ERK signaling pathways could
enhance HIF-1a/VEGF expression in some malignant tu-
mors [33]. From the study about the mechanical regula-
tion of signaling pathway in lung cancer, some scholars
find that inactivation of Akt signaling can inhibit the
growth of human lung cancer cells through reducing
SP1 and p65 protein expression [34]. ERK and PI3K/
AKT pathways can promote tumor cell growth and me-
tastasis and a notable decrease of ERK and PI3K/AKT
activation can be found in TRIM11 knocked down lung
cancer cells [35]. These results are in congruence with
our results that show inhibiting AKT and ERK expres-
sion through specific inhibitors in NSCLs can down-
regulate HIF-1a expression and inhibit angiogenesis.
However, inhibition of ERK expression had no signifi-
cant effect on HIF-1a expression in SCLCs, which was
regulated by the AKT signaling pathways. We hypothe-
sized that the prime cause for this observation was that
the regulatory mechanisms governing tumor properties
are different, based on histological origin. Therefore, we
intend to investigate these regulatory mechanisms fur-
ther in the future.
Hyperthermia is a promising treatment for human
lung cancer, but local recurrence is common, as growth
of residual tumors can be induced by thermal ablation.
Our study demonstrates that hyperthermia inherently
changes the properties of cancer cells, facilitating the
creation of different cancer sublines. These sublines ex-
hibited enhanced viability and angiogenesis potential,
and we determined that HIF-1a/VEGF-A plays a central
role during this biological process. Furthermore, we in-
vestigated the molecular pathways induced/affected by
hyperthermia. We found that HIF-1a expression was in-
duced in heat adapted cell lines and that in NSCLCs this
involves both PI3K/AKT and ERK signaling pathways,
while only the PI3K/AKT signaling pathway is affected
in SCLCs. Altogether, we hope that through investigating
the molecular mechanisms of lung cancer recurrence
following hyperthermia, our work will supply additional
evidence for the use of multidisciplinary synthetic ther-
apies to treat lung cancer.
Conclusions
In this research we find that HIF-1a plays a critical role
in the recurrence of lung cancer following hyperthermia
treatment as the proliferation and angiogenesis potential
of residual NSCLCs and SCLCs are induced by HIF-1a.
However, HIF-1a expression in NSCLCs is regulated by
both the AKT and ERK signaling pathway, but HIF-1a
expression in SCLCs is regulated only by the AKT signaling
pathway. Our study sheds light on the molecular regulatory
mechanisms of lung cancer recurrence following hyper-
thermia treatment.
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